CIK 0001799448 · Non-accelerated filer<br>Smaller reporting company
Aligos Therapeutics, Inc.
Sign in to watch- Ticker
- ALGS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (800) 466-6059
- Business address
- ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-27 | Calhoun Lesley Ann See Remarks | Returned to the company · Stock Option (Right to Buy) | −26,250 | 0 | ||
| 2024-02-27 | BLATT LAWRENCE Chief Executive Officer | Returned to the company · Stock Option (Right to Buy) | −450,000 | 0 | ||
| 2024-02-27 | BLATT LAWRENCE Chief Executive Officer | Returned to the company · Stock Option (Right to Buy) | −323,400 | 0 | ||
| 2024-02-27 | BLATT LAWRENCE Chief Executive Officer | Returned to the company · Stock Option (Right to Buy) | −80,850 | 0 | ||
| 2024-02-27 | Symons Julian A. See Remarks | Returned to the company · Stock Option (Right to Buy) | −200,000 | 0 | ||
| 2024-02-27 | Symons Julian A. See Remarks | Returned to the company · Stock Option (Right to Buy) | −105,000 | 0 | ||
| 2024-02-27 | Symons Julian A. See Remarks | Returned to the company · Stock Option (Right to Buy) | −26,250 | 0 | ||
| 2024-02-27 | Nielsen Jack Director | Returned to the company · Stock Option (Right to Buy) | −15,000 | 0 | ||
| 2024-02-27 | Nuechterlein Carole Director | Returned to the company · Stock Option (Right to Buy) | −15,000 | 0 | ||
| 2024-02-27 | Martell Bridget A Director | Returned to the company · Stock Option (Right to Buy) | −30,000 | 0 | ||
| 2023-10-25 | Nuechterlein Carole Director | Purchase | +7,933,601 | $0.76 | $6.0M | 11,025,941 |
| 2023-10-25 | Nuechterlein Carole Director | Purchase · Warrant (Right to Buy) | +3,966,800 | $0.13 | $496K | 3,966,800 |
| 2023-10-25 | BLATT LAWRENCE Chief Executive Officer | Grant or award | +610,277 | $0.76 | $462K | 1,847,575 |
| 2023-10-25 | BLATT LAWRENCE Chief Executive Officer | Grant or award · Warrants (Right to Buy) | +305,138 | $0.13 | $38K | 305,138 |
| 2023-10-25 | Scopa James Paul Director | Grant or award | +183,083 | $0.76 | $139K | 183,083 |
| 2023-10-25 | Scopa James Paul Director | Grant or award · Warrant (Right to Buy) | +91,541 | $0.13 | $11K | 91,541 |
| 2023-09-08 | McClure Matthew W. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +48,000 | 48,000 | ||
| 2023-09-08 | Calhoun Lesley Ann See Remarks | Grant or award · Stock Option (Right to Buy) | +48,000 | 48,000 | ||
| 2023-09-08 | Quan Lucinda Y. See Remarks | Grant or award · Stock Option (Right to Buy) | +48,000 | 48,000 | ||
| 2023-09-08 | Symons Julian A. See Remarks | Grant or award · Stock Option (Right to Buy) | +48,000 | 48,000 |
Page 4 of 12 · 238 trades